
Jul 25, 2026
Reputation House Published Sector-Wide Analysis of Digital Reputation Across Leading U.S. Pharma Companies
A recent analysis by Reputation House reveals that digital reputational risks for leading U.S. pharmaceutical companies are deeply rooted in structural issues rather than isolated incidents. The study evaluated 17 major firms, focusing on how their digital presence is influenced by historical legal challenges and regulatory actions, particularly as AI-generated content increasingly shapes public perception.Using its AI-powered platform, Risk Check, Reputation House assessed the digital reputatio









